Besides Japan, Iunderstand that Remestemcel-L is also approved in Canada and New Zealand. The USA may be thelarge and preferred market to crack, but I don’t know, why has MSB seemingly neglectedto advance the product in other jurisdictions at the same time and build uponthe results from Japan.
I don’t know, but I getthe distinct feeling that there is little difference between the FDA and the Americangun lobby. Everyone seemingly decries all the deaths and suffering, but deepdown there is not the will to affect any change – they simply don’t care.
By all means pursue theUSA; too late to back-up now; but with an inventory stockpile why wouldn’t MSB belooking to deploy in areas where we already have approval? E.g put that idle sales team to work over the border in Canada.
MSB 2022 - The road to commercialisation, page-1018
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |